Global uncertainties over the past two years, including US President Donald Trump’s tariff threats, price erosion in the generics market, and a Big Pharma shift towards biologics are forcing Indian drugmakers to seek new avenues of growth.
Overseas acquisitions: Indian drugmakers shop for deals abroad as they move away from generics
